Efficacy and safety of pan-genotypic Sofosbuvir and Velpatasvir in patients with Hepatitis C reinfection following attainment of sustained virological response with NS5A inhibitors

Abstract

Background and Aim: Directly acting antivirals (DAAs) have revolutionised the management of Hepatitis C virus (HCV) infection. While easy access to DAAs through national programmes is helping the global fight against the scourge of HCV, reinfections are also rising amongst those who continue to engage in high-risk practices. There is little data available on the treatment of HCV reinfection following the attainment of sustained virological response (SVR) with NS5A inhibitors.